Skip to content
DataLookout
Menu

DO-01NCT06819007

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Eligibility criteria shortened, about 358 words
    • Trial sites expanded: 208 → 232 locations
    • Secondary endpoints: 5 to 28
  2. Minor Trial sites expanded: 205 → 208 locationsv17
  3. Minor Trial sites expanded: 193 → 205 locationsv16
  4. Minor Trial sites expanded: 180 → 193 locationsv15
  5. Minor Study sites: 165 to 180v14
Show 12 earlier versionsHide 12 earlier versions
  1. Minor Study sites: 138 to 165v13
  2. Notable Eligibility criteria expanded, about 12 wordsv12
  3. Minor Study sites: 110 to 138v11
  4. Minor Study sites: 84 to 110v10
  5. Minor Study sites: 59 to 84v9
  6. Minor Study sites: 35 to 59v8
  7. Minor Study sites: 19 to 35v7
  8. Minor Study sites: 12 to 19v6
  9. Minor Study sites: 3 to 12v5
  10. Minor Study sites: 2 to 3
    • Study title expanded, about 1 word
    v4
  11. Minor Study sites: 1 to 2
    • Start date: Mar 18, 2025 to Mar 19, 2025
    v3
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 1, 2025 to Mar 18, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ Population
Timeframe: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months

Secondary (28)

Overall Survival (OS) in the HER2 IHC 3+/2+ Population
PFS by BICR in the HER2 IHC 3+/2+/1+ Population
OS in the HER2 IHC 3+/2+/1+ Population
PFS by the Investigator in HER2 IHC 3+/2+ Population
PFS by the Investigator in HER2 IHC 3+/2+/1+ Population
Show 23 moreShow less
Progression Free Survival 2 (PFS2) by the Investigator in HER2 IHC 3+/2+ Population
PFS2 by the Investigator in HER2 IHC 3+/2+/1+ Population
Confirmed Objective Response (OR) by BICR in HER2 IHC 3+/2+ Population
Confirmed OR by the Investigator in HER2 IHC 3+/2+ Population
Confirmed OR by BICR in HER2 3+/2+/1+ Population
Confirmed OR by the Investigator in HER2 IHC 3+/2+/1+ Population
Duration of Response (DoR) by BICR in HER2 IHC 3+/2+ Population
DoR by the Investigator in HER2 IHC 3+/2+ Population
DoR by BICR in HER2 IHC 3+/2+/1+ Population
DoR by the Investigator in HER2 IHC 3+/2+/1+ Population
Time to First Subsequent Treatment (TFST) in HER2 IHC 3+/2+ Population
TFST in HER2 IHC 3+/2+/1+ Population
Time to Second Subsequent Treatment (TSST) in HER2 IHC 3+/2+ Population
TSST in HER2 3+/2+/1+ Population
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Change from Baseline in Physical Function from European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 30 (QLQ-C30)
Change from Baseline in Pain from EORTC QLQ-C30
Change from Baseline in Global Health Status/Overall Quality of Life (GHS/Overall QoL) Scales from EORTC QLQ-C30
Change from Baseline in Abdominal/Gastrointestinal (GI) Symptoms from EORTC Quality of Life Questionnaire Ovarian Cancer Module 28 (QLQ-OV28)
Percentage of Participants With Confirmed Deterioration for Physical function, Pain, GHS/Overall QoL scales from EORTC QLQ-C30
Percentage of Participants With Confirmed Deterioration Abdominal/Gastrointestinal Symptoms from EORTC QLQ-OV28
Time to Confirmed Deterioration for Physical Function, Pain, GHS/Overall QoL Scales from EORTC QLQ-C30
Time to Confirmed Deterioration for Abdominal/Gastrointestinal Symptoms from EORTC QLQ-OV28

Arms and interventions

Treatment Arm AExperimental

Participants will receive T-DXd in combination with bevacizumab.

Treatment Arm BActive comparator

Participants will receive bevacizumab monotherapy.

Drugs: Trastuzumab Deruxtecan, Bevacizumab

Sites

232 sites in 26 countries

United States 33, China 27, Spain 19, Japan 16, Italy 15, Germany 11, France 10, India 10, South Korea 10, Brazil 9, Australia 8, Taiwan 7, Bulgaria 6, Israel 6, United Kingdom 6, Belgium 5, Czechia 5, Greece 5, Malaysia 5, Hungary 4, Romania 4, Denmark 3, Sweden 3, Poland 2, Singapore 2, Austria 1